Genovis launches FabULOUS®Fab kit
Genovis is launching a further development of FabULOUS® that will be marketed under the name FabULOUS®Fab kit. The product will be presented at the annual conference of the American Society for Mass Spectrometry (ASMS) in San Antonio next week.
Genovis’ products are marketed under the name SmartEnzymes and with FabULOUS®Fab kit Genovis can now offer customers who work with antibodies from mice a product that quickly and easily cleaves and purifies intact Fab fragments. Antibodies from mice are frequently used in preclinical research for various types of analysis.
“The FabULOUS® kit is yet another example of Genovis’ ambition to provide products that facilitate work and reduce time for users. Our offer is now further strengthened with a product that specifically targets those who work with antibodies from mice. Not only does the product improve the quality and yield of the fragments that the customer generates, but we have also simplified handling and significantly reduced the time compared with currently available technologies,” says Fredrik Olsson, CEO of Genovis.
For further information about the FabULOUS®Fab kit: http://www.genovis.com/fabulous-fabkit
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 firstname.lastname@example.org
Genovis is a global company that offers enzyme products that facilitate development and quality control of biologics to customers in the pharmaceutical and medical technology industries. The Company markets several enzyme products (“SmartEnzymes”) in innovative product formats all over the world.
The organization consists of Genovis AB and the wholly owned subsidiary Genovis Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North American market and Genovis AB handles sales in the rest of the world. Genovis shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s Certified Adviser, t: +46(0) 31 745 50 00.
This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.